NardosinoneCAS# 23720-80-1 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 23720-80-1 | SDF | Download SDF |
| PubChem ID | 168136 | Appearance | Colorless crystals |
| Formula | C15H22O3 | M.Wt | 250.33 |
| Type of Compound | Sesquiterpenoids | Storage | Desiccate at -20°C |
| Solubility | DMSO : 250 mg/mL (998.68 mM; Need ultrasonic) | ||
| Chemical Name | (3aR,9R,9aR,9bS)-1,1,9,9a-tetramethyl-3a,4,7,8,9,9b-hexahydronaphtho[2,1-c]dioxol-5-one | ||
| SMILES | CC1CCC=C2C1(C3C(CC2=O)OOC3(C)C)C | ||
| Standard InChIKey | KXGHHSIMRWPVQM-JWFUOXDNSA-N | ||
| Standard InChI | InChI=1S/C15H22O3/c1-9-6-5-7-10-11(16)8-12-13(15(9,10)4)14(2,3)18-17-12/h7,9,12-13H,5-6,8H2,1-4H3/t9-,12-,13+,15+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Nardosinone is an enhancer of nerve growth factor and possesses a wide range of pharmacological effects, including sedative, adaptogen-like, anti-depressive, anti-leukemic, anti-tumorous, and anti-trypanosomal activities. It has a wide spectrum of targets including PI3K,Akt,MEK,ERK, PKA, MAPK. |
| Targets | PI3K | Akt | mTOR | MEK | ERK | PKA | cAMP | PKC | MAPK |
| In vitro | Nardosinone protects H9c2 cardiac cells from angiotensin II-induced hypertrophy.[Pubmed: 24337842]J Huazhong Univ Sci Technolog Med Sci. 2013 Dec;33(6):822-6.Pathological cardiac hypertrophy induced by angiotensin II (AngII) can subsequently give rise to heart failure, a leading cause of mortality. Nardosinone is a pharmacologically active compound extracted from the roots of Nardostachys chinensis, a well-known traditional Chinese medicine.
Nardosinone improves the proliferation, migration and selective differentiation of mouse embryonic neural stem cells.[Pubmed: 24614893]PLoS One. 2014 Mar 10;9(3):e91260.In this study, we investigated the impact of Nardosinone, a bioactive component in Nardostachys root, on the proliferation and differentiation of neural stem cells.
|
| Kinase Assay | Nardosinone, the first enhancer of neurite outgrowth-promoting activity of staurosporine and dibutyryl cyclic AMP in PC12D cells.[Pubmed: 14604758]Brain Res Dev Brain Res. 2003 Nov 12;145(2):177-83.Nardosinone was isolated as an enhancer of nerve growth factor (NGF) from Nardostachys chinensis [Neurosci. Lett. 273 (1999) 53].
|
| Cell Research | [Nardosinone reduces neuronal injury induced by oxygen-glucose deprivation in primary cortical cultures].[Pubmed: 24358776]Yao Xue Xue Bao. 2013 Sep;48(9):1422-9.The aim of the study is to investigate the effect of Nardosinone (Nar) on neuronal injury induced by oxygen-glucose deprivation (OGD) in primary cortical cultures isolated from embryos at gestational day 14.
|
Nardosinone Dilution Calculator
Nardosinone Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.9947 mL | 19.9736 mL | 39.9473 mL | 79.8945 mL | 99.8682 mL |
| 5 mM | 0.7989 mL | 3.9947 mL | 7.9895 mL | 15.9789 mL | 19.9736 mL |
| 10 mM | 0.3995 mL | 1.9974 mL | 3.9947 mL | 7.9895 mL | 9.9868 mL |
| 50 mM | 0.0799 mL | 0.3995 mL | 0.7989 mL | 1.5979 mL | 1.9974 mL |
| 100 mM | 0.0399 mL | 0.1997 mL | 0.3995 mL | 0.7989 mL | 0.9987 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Platycoside E
Catalog No.:BCN6385
CAS No.:237068-41-6
- Damascenone
Catalog No.:BCN8355
CAS No.:23696-85-7
- Olaquindox
Catalog No.:BCN2538
CAS No.:23696-28-8
- Boc-Ser(Bzl)-OH
Catalog No.:BCC3442
CAS No.:23680-31-1
- Levosulpiride
Catalog No.:BCC4463
CAS No.:23672-07-3
- Stigmast-4-ene-3,6-dione
Catalog No.:BCN5778
CAS No.:23670-94-2
- Vicenin -2
Catalog No.:BCN3013
CAS No.:23666-13-9
- Neogrifolin
Catalog No.:BCN7526
CAS No.:23665-96-5
- Ardisiacrispin A
Catalog No.:BCN2323
CAS No.:23643-61-0
- Clerosterol
Catalog No.:BCN2905
CAS No.:2364-23-0
- Triapine
Catalog No.:BCC5112
CAS No.:236392-56-6
- Z-Asp(OtBu)-OH.DCHA
Catalog No.:BCC2788
CAS No.:23632-70-4
- Chebulic acid
Catalog No.:BCN3260
CAS No.:23725-05-5
- 6-Hydroxy-4-Methylcoumarin
Catalog No.:BCC9206
CAS No.:2373-31-1
- trans-Methylkhellactone
Catalog No.:BCN6919
CAS No.:23733-92-8
- trans-3'-O-Benzoyl-4'-O-methylkhellactone
Catalog No.:BCN6921
CAS No.:23733-95-1
- 4-Amino-3-hydroxybenzoic acid
Catalog No.:BCC8681
CAS No.:2374-03-0
- Rivulobirin E
Catalog No.:BCN5090
CAS No.:237407-59-9
- Methylprednisolone Sodium Succinate
Catalog No.:BCC5629
CAS No.:2375-03-3
- 4-Aminopyrazolo[3,4-d]pyrimidine
Catalog No.:BCC8690
CAS No.:2380-63-4
- Homovanillyl alcohol
Catalog No.:BCN7173
CAS No.:2380-78-1
- 6-Hydroxyindole
Catalog No.:BCN8310
CAS No.:2380-86-1
- Pogostone
Catalog No.:BCN2696
CAS No.:23800-56-8
- Hinesol
Catalog No.:BCC9232
CAS No.:23811-08-7
Nardosinone, the first enhancer of neurite outgrowth-promoting activity of staurosporine and dibutyryl cyclic AMP in PC12D cells.[Pubmed:14604758]
Brain Res Dev Brain Res. 2003 Nov 12;145(2):177-83.
Nardosinone was isolated as an enhancer of nerve growth factor (NGF) from Nardostachys chinensis [Neurosci. Lett. 273 (1999) 53]. Nardosinone (0.1-100 microM) enhanced dibutyryl cyclic AMP (dbcAMP, 0.3 mM)- and staurosporine (10 nM)-induced neurite outgrowth from PC12D cells in a concentration-dependent manner. PD98059 (20 microM), a potent mitogen-activated protein (MAP) kinase kinase inhibitor, partially blocked enhancements of dbcAMP (0.3 mM)- or staurosporine (10 nM)-induced neurite outgrowth by Nardosinone. Nardosinone alone had no effect on the phosphorylation of MAP kinase. The dbcAMP-induced increase in phosphorylation of MAP kinase was not affected by Nardosinone. Staurosporine almost unaffected the phosphorylation of MAP kinase, and Nardosinone potentiated the staurosporine-induced neurite outgrowth without stimulation of the phosphorylation of MAP kinase. Since it is known that MAP kinase signaling is required for neurite outgrowth in PC12D cells, these results suggest that Nardosinone enhances staurosporine- or dbcAMP-induced neurite outgrowth from PC12D cells, probably by amplifying both the MAP kinase-dependent and -independent signaling pathways of dbcAMP and staurosporine. It is also suggested that Nardosinone enhances a downstream step of MAP kinase in the MAP kinase-dependent signaling pathway. Nardosinone is the first enhancer of the neuritogenic action of dbcAMP and staurosporine and may become a useful pharmacological tool for studying the mechanism of action of not only NGF but also both the neuritogenic substances.
Nardosinone protects H9c2 cardiac cells from angiotensin II-induced hypertrophy.[Pubmed:24337842]
J Huazhong Univ Sci Technolog Med Sci. 2013 Dec;33(6):822-826.
Pathological cardiac hypertrophy induced by angiotensin II (AngII) can subsequently give rise to heart failure, a leading cause of mortality. Nardosinone is a pharmacologically active compound extracted from the roots of Nardostachys chinensis, a well-known traditional Chinese medicine. In order to investigate the effects of Nardosinone on AngII-induced cardiac cell hypertrophy and the related mechanisms, the myoblast cell line H9c2, derived from embryonic rat heart, was treated with Nardosinone (25, 50, 100, and 200 mumol/L) or AngII (1 mumol/L). Then cell surface area and mRNA expression of classical markers of hypertrophy were detected. The related protein levels in PI3K/Akt/mTOR and MEK/ERK signaling pathways were examined by Western blotting. It was found that pretreatment with Nardosinone could significantly inhibit the enlargement of cell surface area induced by AngII. The mRNA expression of ANP, BNP and beta-MHC was obviously elevated in AngII-treated H9c2 cells, which could be effectively blocked by Nardosinone at the concentration of 100 mumol/L. Further study revealed that the protective effects of Nardosinone might be mediated by repressing the phosphorylation of related proteins in PI3K/Akt and MEK/ERK signaling pathways. It was suggested that the inhibitory effect of Nardosinone on Ang II-induced hypertrophy in H9c2 cells might be mediated by targeting PI3K/Akt and MEK/ERK signaling pathways.
Nardosinone improves the proliferation, migration and selective differentiation of mouse embryonic neural stem cells.[Pubmed:24614893]
PLoS One. 2014 Mar 10;9(3):e91260.
In this study, we investigated the impact of Nardosinone, a bioactive component in Nardostachys root, on the proliferation and differentiation of neural stem cells. The neural stem cells were isolated from cerebrums of embryonic day 14 CD1 mice. The proliferation of cells was monitored using the cell counting kit-8 assay, bromodeoxyuridine incorporation and cell cycle analysis. Cell migration and differentiation were investigated with the neurosphere assay and cell specific markers, respectively. The results showed that Nardosinone promotes cells proliferation and increases cells migration distance in a dose-dependent manner. Nardosinone also induces the selective differentiation of neural stem cells to neurons and oligodendrocytes, as indicated by the expression of microtubule-associated protein-2 and myelin basic protein, respectively. Nardosinone also increases the expression of phospho-extracellular signal-regulated kinase and phospho-cAMP response element binding protein during proliferation and differentiation. In conclusion, this study reveals the regulatory effects of Nardosinone on neural stem cells, which may have significant implications for the treatment of brain injury and neurodegenerative diseases.
[Nardosinone reduces neuronal injury induced by oxygen-glucose deprivation in primary cortical cultures].[Pubmed:24358776]
Yao Xue Xue Bao. 2013 Sep;48(9):1422-9.
The aim of the study is to investigate the effect of Nardosinone (Nar) on neuronal injury induced by oxygen-glucose deprivation (OGD) in primary cortical cultures isolated from embryos at gestational day 14. MTT method was used to determine the dosage regimen of Nar in primary neuronal cultures and observe the influence of Nar on the neurons suffering OGD; Western blotting analysis was used to detect expressions of protein kinase A (PKA), Ras related protein 1 (Rap1), mitogen-activated protein kinase kinase 1 (MEK1) and phospho-extracellular signal-regulated kinase 1/2 (p-ERK1/2) of OGD-injured or uninjured primary cultured neurons after Nar treatment. Results showed that Nar (50 and 100 micromol x L(-1)) improved the cell viability during OGD damage (P < 0.01) and increased the expression of PKA, Rap1, MEK1 and p-ERK1/2 in injured neurons. Additionally, elevations of PKA, Rapl, MEK1 and p-ERK1/2 in uninjured neurons were caused by Nar (50, 100 and 200 micromol x L(-1)) with a dose-dependent tenclency as well (P < 0.01). In conclusion, Nar could protect against the neuronal injury exposed to OGD, which may be relevant to the promotion of PKA and ERK signaling pathway.
Nardosinone enhances nerve growth factor-induced neurite outgrowth in a mitogen-activated protein kinase- and protein kinase C-dependent manner in PC12D cells.[Pubmed:14501162]
J Pharmacol Sci. 2003 Sep;93(1):122-5.
The mechanism to enhance nerve growth factor (NGF, 2 ng/ml)-induced neurite outgrowth from PC12D cells by Nardosinone isolated from Nardostachys chinensis was examined. It was shown that the potentiation of the NGF-induced neurite outgrowth by Nardosinone was mitogen-activated protein (MAP) kinase-dependent, but was not accompanied by stimulation of NGF-induced increase in MAP kinase phosphorylation. Furthermore, this augmentation of NGF-induced neurite outgrowth was abolished by GF109203X, a protein kinase C (PKC) inhibitor. These results suggest that the enhancement of NGF-induced neurite outgrowth from PC12D cells by Nardosinone involves activation of a down-stream step of the MAP kinase-dependent cascade of NGF coupled with PKC.
